Company Announcement: Hyperfine, Inc. has announced its schedule for upcoming investor conferences to discuss recent milestones and growth catalysts related to their AI-powered portable MR brain imaging system, Swoop®.
Upcoming Conferences: The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and at the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, 2025, both in New York City.
Swoop® System Overview: The Swoop® system is the first FDA-cleared portable magnetic resonance brain imaging device designed for multiple points of care, aiming to enhance patient diagnostics globally.
Accessibility and Impact: Hyperfine's mission focuses on transforming patient care through accessible diagnostic imaging, with the Swoop® system already available in select international markets and cleared for use across all age groups.
HYPR
$0.9472+Infinity%1D
Analyst Views on HYPR
Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.928
Low
2.00
Averages
2.00
High
2.00
Current: 0.928
Low
2.00
Averages
2.00
High
2.00
Lake Street
Buy
maintain
$2
2025-08-14
Reason
Lake Street
Price Target
$2
2025-08-14
maintain
Buy
Reason
Lake Street raised the firm's price target on Hyperfine to $2 from $1.50 and keeps a Buy rating on the shares after the company reported Q2 results and reiterated 2025 guidance for 10%-20% revenue growth. The firm believes a growth inflection supports multiple expansion, the analyst tells investors in a post-earnings note.
B. Riley
Yuan Zhi
Buy
maintain
$1
2025-06-03
Reason
B. Riley
Yuan Zhi
Price Target
$1
2025-06-03
maintain
Buy
Reason
B. Riley
Buy
downgrade
$1
2025-05-15
Reason
B. Riley
Price Target
$1
2025-05-15
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Hyperfine to $1 from $1.20 and keeps a Buy rating on the shares. The Q1 sales miss was driven by the loss of several orders at large academic institutions that were funded by research grants, which was a result of the tension between academic institutions and the current administration, the analyst tells investors in a research note. The firm awaits more clarity in the second half of 2025.
Lake Street
Frank Takkinen
Strong Buy
Initiates
$1.5
2025-03-24
Reason
Lake Street
Frank Takkinen
Price Target
$1.5
2025-03-24
Initiates
Strong Buy
Reason
About HYPR
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
